Skip to main content

Our Journey
Our Technology
Pipeline

Leadership
Investors
Get in Touch

Press Releases

Presentations
Corporate Governance
Press Releases
Stock Information
SEC Filings

Investor Contact

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

Press Releases

Keyword Search

Year

Dec 27, 2022

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 08, 2022

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 01, 2022

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 06, 2022

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 08, 2022

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

Aug 04, 2022

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 22, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 11, 2022

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 17, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jun 02, 2022

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 09, 2022

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 03, 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

May 01, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Apr 04, 2022

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Mar 29, 2022

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 23, 2022

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Mar 08, 2022

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Feb 18, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

©2023 Kala Pharmaceuticals All rights reserved. January 2023

Terms of Use Privacy Statement Accessibility Policy